REVELATION BIOSCIENCES, INC. Debt Conversion, Converted Instrument, Amount
REVELATION BIOSCIENCES, INC. (REVB) reported Debt Conversion, Converted Instrument, Amount of $10.00 thousand for the 12-month period ending 2020-12-31, per its 10-K/A filed 2021-06-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2021-06-16
- REVELATION BIOSCIENCES, INC. debt conversion, converted instrument, amount for fiscal 2020 was $10.00K.
| Period end | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|
| 2020-12-31 | $10.00K 10-K/A · filed 2021-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |